Valgimigli, Marco

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal

Acute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Cited by 9,728

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal

Acute Myocardial Infarction ResearchCardiac Imaging and Diagnostics

Cited by 8,261

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal

Acute Myocardial Infarction ResearchCardiac Imaging and Diagnostics

Cited by 5,037

2013 ESC guidelines on the management of stable coronary artery disease

Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal

Clinical practice guidelines implementationCoronary Interventions and Diagnostics

Cited by 4,510

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study

Biondi-Zoccai, G. G. L., Lotrionte, M., Abbate, A., Testa, L., Remigi, E., Burzotta, F., Valgimigli, M., Romagnoli, E., Crea, F., & Agostoni, P. (2006) · BMJ

Meta-analysis and systematic reviewsPharmaceutical industry and healthcare

Cited by 149

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Role for Substance P–Based Nociceptive Signaling in Progenitor Cell Activation and Angiogenesis During Ischemia in Mice and in Human Subjects

Amadesi, S., Reni, C., Katare, R., Meloni, M., Oikawa, A., Beltrami, A. P., Avolio, E., Cesselli, D., Fortunato, O., Spinetti, G., et al. (2012) · Circulation

Neuropeptides and Animal PhysiologyAngiogenesis and VEGF in Cancer

Cited by 100

Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials

Potpara, T. S., Mujovic, N., Proietti, M., Dagres, N., Hindricks, G., Collet, J.-P., Valgimigli, M., Heidbuchel, H., & Lip, G. Y. H. (2020) · EP Europace

Atrial Fibrillation Management and OutcomesAntiplatelet Therapy and Cardiovascular Diseases

Cited by 98

1-Month or 3-Month DAPT in Women and Men at High Bleeding Risk Undergoing PCI

Kunadian, V., Gitto, M., Vogel, B., Sartori, S., Angiolillo, D. J., Bhatt, D. L., Chehab, B. M., Feng, Y., de la Torre Hernandez, J. M., Krucoff, M. W., et al. (2025) · JACC: Cardiovascular Interventions

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 7